Pulmonx (LUNG) vs Myomo (MYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Myomo (MYO) has outperformed Pulmonx (LUNG) over the past year, gaining 19.5% versus a gain of 1.7%. Over five years, MYO leads with a -89.4% price change compared with -95.5% for LUNG. Pulmonx is the larger company by market cap ($79.0 million vs $57.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | MYO |
|---|---|---|
| Share price | $1.84 | $1.44 |
| Market cap | $79.02M | $57.04M |
| 1-day change | +1.66% | +2.13% |
| YTD return | -18.10% | +54.95% |
| 1-year return | +1.69% | +19.49% |
| 5-year return | -95.45% | -89.43% |
| EPS (TTM) | $-1.15 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.89 | $1.89 |
| 52-week low | $1.13 | $0.605 |
| Distance from 52-week high | -36.33% | -23.61% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.78% | +222.22% |
| Average volume | 477.26K | 493.94K |
| Shares outstanding | 42.95M | 39.61M |
| Employees | 296 | 194 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MYO has outperformed LUNG by 17.8 percentage points over the past year.
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
About Myomo
MYO stock →Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
Health Care · Industrial Specialties · 194 employees
LUNG vs MYO FAQ
Which is bigger, Pulmonx or Myomo?
Pulmonx (LUNG) is larger, with a market capitalization of $79.02M compared with $57.04M for Myomo (MYO).
Which stock has performed better over the past year, LUNG or MYO?
MYO returned +19.49% over the past 12 months, compared with +1.69% for LUNG (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and Myomo in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Pulmonx and Industrial Specialties for Myomo.